NOVARTIS AG

Listed Company
NVSEFCIK 0001114448OTCLarge AcceleratedPharmaceutical PreparationsV8CHFY ends Dec 31
Period
FY 2025
Revenue
Net Income
$13.97B
Total Assets
$110.95B
Equity
Shares Out
1.91B
Op. Cash Flow

Business

Novartis AG is an innovative medicines company that researches, develops, manufactures, markets and sells pharmaceutical and advanced therapy products. It offers a broad portfolio of prescription medicines, gene and cell therapies, radioligand therapies, siRNA and other RNA-based treatments, biologics and small-molecule drugs across multiple therapeutic areas. Its operations are organized into Biomedical Research, Development, Operations and two commercial units (US and International), supported by global corporate functions. Novartis sells products in approximately 120 countries through wholesalers, hospitals, specialty pharmacies, managed care organizations, government agencies and direct-to-patient channels.

Summary from filing dated 2026-02-04

Financials

Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.

Revenue
Net income$13.97B
Total assets$110.95B
Total liabilities$64.40B
Stockholders' equity
Operating cash flow

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro